MedTrace Logo

Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System

NCT04311398 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-05-14

No results posted yet for this study

Summary

Our project intends to independently develop a fully enclosed rapid detection system for a total of 22 pathogens, including SARS-CoV-2, on the basis of the QIAstat-Dx fully automatic multiple PCR detection platform. The reasonably designed experiments are used to verify the performance of the cartridge detection and prove its clinical application value. The 22 pathogens tested in this project includes 4 coronavirus subtypes, A / B flu, parainfluenza virus, respiratory syncytial virus, etc., which is of great significance for the differential diagnosis of similar patients.

Conditions

Interventions

DIAGNOSTIC_TEST

New QIAstat-Dx fully automatic multiple PCR detection platform

We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-13
Primary Completion
2020-06-01
Completion
2020-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04311398 on ClinicalTrials.gov